CLC Number:

[1]	LU Mengjie, LIU Yuxiu, LU Guangming, ZHANG Longjiang, HUANG Wei, GE Aichen. Sample size calculation for single-arm OPC trials with multi endpoints [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 917-921.
[2]	LI Yun, LI Bingsheng, ZHANG Weifang, LI Yixiu, LI Chun, PENG Juan, LAI Xin, ZHU Jing, XU Ruilai, XIONG Aizhen. Association study of miR-146a G>C polymorphisms with susceptibility of hepatocellular carcinoma in the Chinese population: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 779-786.
[3]	. [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2000, 5(3): 279-283.
[4]	. [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2000, 5(2): 164-165.
[5]	. [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1999, 4(3): 226-228.
[6]	. [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1996, 1(1): 61-64.
[7]	. [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1996, 1(2): 131-135.
[8]	. [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1996, 1(2): 136-141.
[9]	. [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1996, 1(2): 142-145.

PDF (PC)

Knowledge